You wouldn’t think twice about asking your asthma patients to quit smoking, but have you ever asked them whether they have allergic rhinitis?
Not such a strange question if you consider that 80% of patients with #asthma have #allergicrhinitis and the presence of uncontrolled rhinitis has the same effect on asthma control as smoking! On the flip side, treating rhinitis effectively improves asthma outcomes. This is because what happens in the nose affects the lungs and vice versa. Therefore, it’s really important to treat both conditions together to optimise outcomes. Don’t forget about rhinitis when reviewing asthma patients! Dr. Toni Hazell, a GP and eLearning Fellow at The Royal College of General Practitioners (RCGP), and Professor David Price from #OPRI discuss more about this in RCGP’s latest #podcast, “Asthma, allergic rhinitis and one airway”.
OPRI is excited to share a milestone in asthma phenotype recognition!
The ISAR #publication titled, ”Eosinophilic and Non eosinophilic Asthma, An Expert Consensus Framework to Characterize Phenotypes in a Global Real-Life Severe Asthma Cohort” found that >80% patients in severe asthma centres have eosinophilic asthma which is more than previously thought. The eosinophilic phenotype was identified using #ISAR’s Gradient Eosinophilic Phenotype Algorithm, an evidence-based and consensus-driven algorithm using readily available variables in real life. The value of this algorithm, is that physicians can now easily recognize the type of asthma their patients have, identify treatable traits and confidently prescribe phenotype-directed treatments.
With nearly 7000 downloads as of 31 December 2021, it was the TOP downloaded paper on chestjournal.org and ScienceDirect in 2021!
Are severe asthma patients getting the right treatment?
Research has shown that you can’t take a one-size-fits-all approach to severe asthma management due to differences in phenotypes. So, we developed the International Severe Asthma Registry (ISAR) Eosinophil Phenotype Gradient Algorithm to quantify the eosinophilic phenotype in severe asthma. Using this algorithm, we found 50.3% of patients in UK primary care to be eosinophilic, 22.2% were likely eosinophilic, 21.9% were unlikely eosinophilic and just 5.6% to be non-eosinophilic. What’s more, eosinophilic patients had more exacerbations and greater healthcare resource utilization. In the age of personalized medicine, eosinophilic phenotyping will allow asthma patients to be identified and categorized with and without eosinophilic asthma in primary care and to be referred for phenotype-targeted treatment.
The February issue of REG’s newsletter is out – and ISAR has been featured in it!
This ISAR report contains exciting details on the ISAR Open Research Meeting and ISAR Steering Committee Meeting (17th March 2022), as well as the ISAR Sessions at the REG Summit 2022 (19th March 2022). Read about the Spectator Briefings podcast featuring ISAR, in addition to our usual operational, publications, and research updates here: https://lnkd.in/gYGYdpvG
International Severe Asthma Registry (ISAR) Newsletter.
We are delighted to share the December 2021 issue of the ISAR biannual newsletter! Read about our continued growth in patient recruitment numbers, research and publication updates, e-Posters presented at the ERS congress 2021, quality improvement initiatives, and past and upcoming events.
We are delighted for Dr Dermot Ryan to share with you an important challenge in the management of severe asthma – identifying patients with hidden disease. Severe asthma patients who are referred to specialist care tend to manage their disease better, and lack of referrals have been associated with worse outcomes, including death. Identifying severe asthma patients hidden in primary care is a challenge, but it is necessary to adequately treat their disease.
ISAR recently held a virtual collaborators meeting on 15th September and it was a huge success! With 88 people from 25 countries spread across the globe, it was an excellent opportunity to get our collaborators up to speed on the latest updates from ISAR, as well as provide a forum for productive discussion.